Chronic effects of subuctaneous interleukin-2 therapy on soluble interleukin-2 receptors in advanced small cell lung cancer

S. Viviani, P. M. Salvini, P. Bidoli, E. Camerini, S. Spinazze, F. Arienti, L. Rivoltini, V. Motta

Research output: Contribution to journalArticle

Abstract

The increase in IL-2 receptor serum levels is one of the most typical changes in immune parameters during IL-2 cancer immunotherapy. To better define the effects of prolonged IL-2 injerction on SIL-2R levels, we evaluated 7 advanced small cell lung cancer patients who received IL-2 subcutaneously at a daily dose of 9x106 IU/m2/12h for two days followed by 3x106 IU/m2/12h for 18 days (5 days/week for 4 weeks). Moreover, four patients were also evaluated during the second IL-2 cycle. Venous blood samples were drawn before and at weekly intervals during IL-2 therapy. Mean SIL-2R serum levels rapidly increased with the start of IL-2 injection, and they were signicantly higher than the baseline levels throughout the immunotherapy cycle. The increase in mean SIL-2R levels was higher inpatients with progressive disease than in those with response or stable disease, but the difference was not significant. Finally, the increase in mean SIL-2R concentrations during the second IL-2 cycle was not significantly different from that seen during the first one. The present study confirms that IL-2 administration determines an evident increase in SIL-2R levels; moreover, it would demonstrate that re-exposure to IL-2 after a rest period does not induce a more pronounced SI-2R release.

Original languageEnglish
Pages (from-to)21-24
Number of pages4
JournalInternational Journal of Biological Markers
Volume8
Issue number1
Publication statusPublished - 1993

Fingerprint

Interleukin-2 Receptors
Small Cell Lung Carcinoma
Interleukin-2
Cells
Therapeutics
Immunotherapy
Serum
Inpatients
Blood
Injections

Keywords

  • cancer immunotherapy
  • interleukin-2
  • soluble interleukin-2 receptor

ASJC Scopus subject areas

  • Biochemistry
  • Immunology

Cite this

Chronic effects of subuctaneous interleukin-2 therapy on soluble interleukin-2 receptors in advanced small cell lung cancer. / Viviani, S.; Salvini, P. M.; Bidoli, P.; Camerini, E.; Spinazze, S.; Arienti, F.; Rivoltini, L.; Motta, V.

In: International Journal of Biological Markers, Vol. 8, No. 1, 1993, p. 21-24.

Research output: Contribution to journalArticle

@article{c5cb14f081b94eb9ae277290f18863ad,
title = "Chronic effects of subuctaneous interleukin-2 therapy on soluble interleukin-2 receptors in advanced small cell lung cancer",
abstract = "The increase in IL-2 receptor serum levels is one of the most typical changes in immune parameters during IL-2 cancer immunotherapy. To better define the effects of prolonged IL-2 injerction on SIL-2R levels, we evaluated 7 advanced small cell lung cancer patients who received IL-2 subcutaneously at a daily dose of 9x106 IU/m2/12h for two days followed by 3x106 IU/m2/12h for 18 days (5 days/week for 4 weeks). Moreover, four patients were also evaluated during the second IL-2 cycle. Venous blood samples were drawn before and at weekly intervals during IL-2 therapy. Mean SIL-2R serum levels rapidly increased with the start of IL-2 injection, and they were signicantly higher than the baseline levels throughout the immunotherapy cycle. The increase in mean SIL-2R levels was higher inpatients with progressive disease than in those with response or stable disease, but the difference was not significant. Finally, the increase in mean SIL-2R concentrations during the second IL-2 cycle was not significantly different from that seen during the first one. The present study confirms that IL-2 administration determines an evident increase in SIL-2R levels; moreover, it would demonstrate that re-exposure to IL-2 after a rest period does not induce a more pronounced SI-2R release.",
keywords = "cancer immunotherapy, interleukin-2, soluble interleukin-2 receptor",
author = "S. Viviani and Salvini, {P. M.} and P. Bidoli and E. Camerini and S. Spinazze and F. Arienti and L. Rivoltini and V. Motta",
year = "1993",
language = "English",
volume = "8",
pages = "21--24",
journal = "International Journal of Biological Markers",
issn = "0393-6155",
publisher = "Wichtig Publishing Srl",
number = "1",

}

TY - JOUR

T1 - Chronic effects of subuctaneous interleukin-2 therapy on soluble interleukin-2 receptors in advanced small cell lung cancer

AU - Viviani, S.

AU - Salvini, P. M.

AU - Bidoli, P.

AU - Camerini, E.

AU - Spinazze, S.

AU - Arienti, F.

AU - Rivoltini, L.

AU - Motta, V.

PY - 1993

Y1 - 1993

N2 - The increase in IL-2 receptor serum levels is one of the most typical changes in immune parameters during IL-2 cancer immunotherapy. To better define the effects of prolonged IL-2 injerction on SIL-2R levels, we evaluated 7 advanced small cell lung cancer patients who received IL-2 subcutaneously at a daily dose of 9x106 IU/m2/12h for two days followed by 3x106 IU/m2/12h for 18 days (5 days/week for 4 weeks). Moreover, four patients were also evaluated during the second IL-2 cycle. Venous blood samples were drawn before and at weekly intervals during IL-2 therapy. Mean SIL-2R serum levels rapidly increased with the start of IL-2 injection, and they were signicantly higher than the baseline levels throughout the immunotherapy cycle. The increase in mean SIL-2R levels was higher inpatients with progressive disease than in those with response or stable disease, but the difference was not significant. Finally, the increase in mean SIL-2R concentrations during the second IL-2 cycle was not significantly different from that seen during the first one. The present study confirms that IL-2 administration determines an evident increase in SIL-2R levels; moreover, it would demonstrate that re-exposure to IL-2 after a rest period does not induce a more pronounced SI-2R release.

AB - The increase in IL-2 receptor serum levels is one of the most typical changes in immune parameters during IL-2 cancer immunotherapy. To better define the effects of prolonged IL-2 injerction on SIL-2R levels, we evaluated 7 advanced small cell lung cancer patients who received IL-2 subcutaneously at a daily dose of 9x106 IU/m2/12h for two days followed by 3x106 IU/m2/12h for 18 days (5 days/week for 4 weeks). Moreover, four patients were also evaluated during the second IL-2 cycle. Venous blood samples were drawn before and at weekly intervals during IL-2 therapy. Mean SIL-2R serum levels rapidly increased with the start of IL-2 injection, and they were signicantly higher than the baseline levels throughout the immunotherapy cycle. The increase in mean SIL-2R levels was higher inpatients with progressive disease than in those with response or stable disease, but the difference was not significant. Finally, the increase in mean SIL-2R concentrations during the second IL-2 cycle was not significantly different from that seen during the first one. The present study confirms that IL-2 administration determines an evident increase in SIL-2R levels; moreover, it would demonstrate that re-exposure to IL-2 after a rest period does not induce a more pronounced SI-2R release.

KW - cancer immunotherapy

KW - interleukin-2

KW - soluble interleukin-2 receptor

UR - http://www.scopus.com/inward/record.url?scp=0027335878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027335878&partnerID=8YFLogxK

M3 - Article

C2 - 8388428

AN - SCOPUS:0027335878

VL - 8

SP - 21

EP - 24

JO - International Journal of Biological Markers

JF - International Journal of Biological Markers

SN - 0393-6155

IS - 1

ER -